NCT00540150

Compatibility and Immunogenicity of a Short Specific Immunotherapy (SIT) in Contrast to Classic Specific Immunotherapy

Compatibility and Immunogenicity of a Short Specific Immunotherapy (SIT) in Contrast to Classic Specific Immunotherapy in a Randomized Study Depending on Mite-Depot Supplement in Children and Adolescents With Allergic Bronchial Asthma.

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 34 (actual)
• Sponsor: Johann Wolfgang Goethe University Hospital · Academic / Other
• Sex: All
• Age: 6 Years – 18 Years
• Healthy volunteers: Not accepted

Summary

We wanted to examine the immunogenicity and safety of a shortened specific immunotherapy in contrast to the standard specific immunotherapy. Therefore, we challenged 12 patients for 14 weeks with the standard specific scheme and 22 patients for 6 weeks with the shortened scheme.

Detailed description

see above

Conditions

• Immunotherapy

Interventions

Type	Name	Description
BIOLOGICAL	specific subcutaneous immunotherapy house dust mite allergoid (Novo-Helisen Depot)	We treat each patient with mite-allergen following the two different protocols.

Timeline

• Start date: 2004-05-01
• Completion: 2005-03-01
• First posted: 2007-10-05
• Last updated: 2007-10-05

Locations

1 site across 1 country: Germany